BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In this sense, CML is also an excellent candidate for evaluating gene therapy strategies, since it is well-established that all pathological features of the disease can be attributed to a single genetic event, the fusion of the BCR and ABL genes [11,12,13,14,15,16].